Insurance coverage and financing landscape for HIV treatment and prevention in the USA

• Published in: The Lancet (British edition) Vol. 397; no. 10279; pp. 1127 - 1138
• Main Authors: Kates, Jennifer, Dawson, Lindsey, Horn, Tim H, Killelea, Amy, McCann, Nicole C, Crowley, Jeffrey S, Walensky, Rochelle P
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 20.03.2021; Elsevier B.V; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; AIDS; AIDS treatment; Drug therapy; Financing; Health care; HIV; HIV (Viruses); Human immunodeficiency virus; Insurance; Insurance coverage; Medicaid; Medical law; Medically uninsured persons; Patient Protection & Affordable Care Act 2010-US; Prevention; United States > US
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(21)00397-4

In 2010, the US health insurance system underwent one of its most substantial transformations with the passage of the Affordable Care Act, which increased coverage for millions of people in the USA, including those with and at risk of HIV. Even so, the system of HIV care and prevention services in the USA is a complex patchwork of payers, providers, and financing mechanisms. People with HIV are primarily covered by Medicaid, Medicare, private insurance, or a combination of these; many get care through other programmes, particularly the Ryan White HIV/AIDS Program, which serves as the nation's safety net for people with HIV who remain uninsured or underinsured but offers modest to no support for prevention services. While uninsurance has drastically declined over the past decade, the USA trails other high-income countries in key HIV-specific metrics, including rates of viral suppression. In this paper in the Series, we provide an overview of the coverage and financing landscape for HIV treatment and prevention in the USA, discuss how the Affordable Care Act has changed the domestic health-care system, examine the major programmes that provide coverage and services, and identify remaining challenges.